Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) EPS (Weighted Average and Diluted) (2019 - 2025)

Assembly Biosciences has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at $2.48 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at $2.48 for Q4 2025, up 257.96% from a year ago — trailing twelve months through Dec 2025 was -$0.74 (up 88.99% YoY), and the annual figure for FY2025 was -$0.55, up 91.78%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $2.48 at Assembly Biosciences, up from -$0.72 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for ASMB hit a ceiling of $2.48 in Q4 2025 and a floor of -$21.62 in Q4 2022.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$1.37 (2021), compared with a mean of -$2.44.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): crashed 1478.1% in 2022 and later surged 257.96% in 2025.
  • Assembly Biosciences' EPS (Weighted Average and Diluted) stood at -$1.37 in 2021, then tumbled by 1478.1% to -$21.62 in 2022, then surged by 91.81% to -$1.77 in 2023, then increased by 11.3% to -$1.57 in 2024, then surged by 257.96% to $2.48 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were $2.48 (Q4 2025), -$0.72 (Q3 2025), and -$1.33 (Q2 2025) per Business Quant data.